RA Session II served as the CEO of Taysha Gene Therapies, Inc. from November 2020 to December 2022 before transitioning to a board member role. He has a background deep in the biotech industry, previously holding senior positions at leading...
RA Session II served as the CEO of Taysha Gene Therapies, Inc. from November 2020 to December 2022 before transitioning to a board member role. He has a background deep in the biotech industry, previously holding senior positions at leading companies like AveXis and BridgeBio Pharma. During his time at Taysha, he oversaw significant growth and strategic directions for the company focused on gene therapy. RA’s compensation in 2021 reached a high of approximately $4.57 million, largely boosted by substantial performance bonuses and stock awards, reflecting his impact on the company. Remarkably, he was granted over 769,000 shares of stock that were valued significantly at the end of 2020, indicating his vested interest in the company’s success. Interestingly, after his resignation from the CEO role, RA stepped away from the Board in March 2023, marking a significant change in Taysha's leadership.